Project Grant R43HL158306
- The federal Project Grant award, valued at $413,595, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports the development of a "Magnetic Rotational Platform for Coronary Lesions" by Unandup, LLC, a technology firm in St. Louis, Missouri. The project aims to create an innovative medical device technology that leverages magnetic fields to improve the treatment of severe coronary artery...
- This $397,034 Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the Massachusetts Institute of Technology (MIT) on September 1, 2025 supports the development of a Transcatheter Manufacturing Toolkit for Minimally-Invasive and Patient-Specific Device-Based Stroke Prevention. The key product being developed under this grant is a system to create fully-soft, personalized medical implants directly inside the patient's body in a...
- This federal Project Grant award of $313,302.00, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a novel lead delivery platform for precise cardiac conduction system pacing. The key products and services to be delivered include a 3D pre-shaped delivery catheter with features to enable physicians to monitor pacing parameters, implant depth, and cardiac conduction system capture during the implantation...
- The federal Project Grant award by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $534,761 to the University of California, Los Angeles (UCLA) to develop "Magnetoelastic Vascular Grafts" (MVGs). The MVGs are a transformative platform technology that can wirelessly and continuously monitor blood flow and detect stenosis (narrowing) in vascular grafts, a common issue affecting nearly 40% of grafts within 2 years of implantation. The...
- This $499,103 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports Alleviant Medical, Inc. in two key efforts: Implementing high-volume manufacturing capabilities and establishing production readiness for the ALV1 system, a novel transcatheter approach to relieve left atrial pressure in heart failure patients without requiring a cardiac implant. Executing reimbursement and marketing initiatives to...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $293,653 to 3DT Holdings, LLC to develop a software tool for optimizing cardiac resynchronization therapy (CRT), conduction system pacing (CSP), and left ventricular endocardial pacing (LVEP) therapies. The goal is to reduce non-responder rates and improve patient identification for these treatments, especially for patients with...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $1,024,635 project grant to Corvion, Inc. to develop a Totally Implanted Left Ventricular Assist Device (TI-LVAD). The TI-LVAD aims to reduce complications and enhance quality of life for heart failure patients by eliminating the need for a percutaneous driveline and external power supply. The key innovation is a hybrid magnetically levitated blood pump that requires...
- The National Heart, Lung, and Blood Institute (NHLBI), through its Cardiovascular Diseases Research grant program (CFDA 93.837), awarded $1,032,585 to Aveera Medical Inc. on September 1, 2025. The funding supports Aveera Medical's project to develop and evaluate their novel Native Deep Vein Arterialization (NDVA) procedure using the Boomerang System. This technology aims to reduce major amputations and improve quality of life for patients with "no-option" chronic limb-threatening...
- The National Heart, Lung, and Blood Institute awarded a $314,362 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Nimble Surgical Incorporated for the project "FLEXLOCK - A NOVEL ANCHORING GUIDE CATHETER TO SIMPLIFY TRANSRADIAL COMPLEX PERCUTANEOUS CORONARY INTERVENTIONS." The grant supports the development of an innovative, manually operable FlexLock guide catheter featuring an anchoring tip to provide simultaneous active and passive support for...
- This $323,230 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a multi-channel radiofrequency and pulsed field energy source generator for cardiac ablation procedures. The award recipient, Sirona Medical Technologies, Inc., is developing a novel catheter device and customizable energy generator to improve the safety and precision of cardiac ablation treatments. Key product features include...
MAGNETIC ROTATIONAL EXPLORATORY PLATFORM FOR CORONARY LESIONS - CARDIOVASCULAR DISEASE (CVD) IS THE LEADING CAUSE OF MORTALITY IN THE UNITED STATES (US), RESULTING IN 850,000 ANNUAL DEATHS, OF WHICH NEARLY 400,000 ARE ASSOCIATED WITH CORONARY HEART DISEASE (CHD) AND MYOCARDIAL INFARCTION (MI). BY 2030, GLOBAL ANNUAL DEATHS WILL EXCEED 20 MILLION. MORE THAN 90 MILLION US ADULTS CURRENTLY LIVE WITH CVD, WHICH IS ASSOCIATED WITH AN ANNUAL ECONOMIC BURDEN OF MORE THAN $330 BILLION. TOGETHER, MI AND CHD ARE THE MOST EXPENSIVE CONDITIONS TREATED IN US HOSPITALS, TOTALING MORE THAN $20 BILLION EACH YEAR, WITH COSTS EXPECTED TO DOUBLE BY 2030. PERCUTANEOUS CORONARY INTERVENTION (PCI) IS AN EFFECTIVE STRATEGY TO RESTORE BLOOD FLOW FOR OBSTRUCTIVE CHD. HOWEVER, WHILE NEARLY 950,000 PCI PROCEDURES ARE PERFORMED EACH YEAR IN THE US, NAVIGATING TORTUOUS VESSELS IS CHALLENGING AND ENABLING STENT EXPANSION WITHIN SEVERELY CALCIFIED OCCLUSIONS OFTEN FAILS, WHICH ARE OBSERVED IN ~35% AND ~20% OF PROCEDURES, RESPECTIVELY. ROTATIONAL ATHERECTOMY (RA) AND ORBITAL ATHERECTOMY (OA) ARE INCREASINGLY USED TO DEBULK OTHERWISE UNTREATABLE LESIONS TO ENABLE PCI, WITH RECENT STUDIES CONFIRMING RA AND OA IMPROVE STENT DELIVERABILITY VS. STANDARD PCI WITHOUT NEGATIVELY AFFECTING OUTCOMES. TO DEBULK SEVERELY CALCIFIED LESION, RA/OA DEVICES EMPLOY LONG (>300CM) STIFF DRIVESHAFTS WHICH SPIN BURRS/CROWNS AT SPEEDS UP TO 180,000 RPM. FOR BOTH RA AND OA, THE INFLEXIBLE DRIVESHAFT OFTEN HINDERS ACCESS WITHIN TORTUOUS VASCULATURE. THE HIGH SPEEDS EMPLOYED ARE NECESSARY TO STABILIZE THE BURR/CROWN ABOUT A GUIDEWIRE, WITHOUT WHICH, THE TIP WOULD DANGEROUSLY WHIP. HOWEVER, THE NEED FOR EXTREME ROTATIONAL SPEEDS GREATLY INCREASES THE COMPLEXITY OF RA/OA SYSTEMS AND PRESENTS RISKS, WHICH INCLUDE 1) THERMAL INJURY DUE TO DRIVESHAFT FRICTION, 2) ARTERIAL ABRASION AND PERFORATION, 3) GUIDEWIRE SHATTERING, 4) BURR/CROWN ENTRAPMENT, AND 5) EMBOLIC DEBRIS WITHIN THE DISTAL VASCULATURE. TO REDUCE THE RISK OF TRAUMATIC INJURY, RA AND OA DEVICES CANNOT BE USED FOR MORE THAN FIVE MINUTES. UNANDUP HAS DEVELOPED AN INTERVENTIONAL CARDIOLOGY PLATFORM CONSISTING OF A MAGNETIC ACCESS GUIDEWIRE AND AN OVER-THE-WIRE ROTATIONAL ATHERECTOMY CATHETER WHICH ARE CONTROLLED USING MAGNETIC FIELDS 100X WEAKER THAN AN MRI. THE MAGNETIC GUIDEWIRE OVERCOMES VESSEL TORTUOSITY TO IMPROVE LESION ACCESS, A DESIRABLE FEATURE FOR PCI IN GENERAL. FOR THE MAGNETIC ATHERECTOMY CATHETER, APPLYING MAGNETIC FORCES DIRECTLY TO THE BURR ELIMINATES THE NEED FOR 100X HIGHER DRIVESHAFT SPEEDS TO STABILIZE TIP ROTATION. RESULTINGLY, SAFER AND MORE EFFICACIOUS DEBULKING IS ACHIEVED. FURTHER, DRIVESHAFT REMOVAL ENABLES CONCURRENT ASPIRATION OF EMBOLIC DEBRIS NEAR THE BURR, A FEATURE NOT POSSIBLE WITH CURRENT ATHERECTOMY DEVICES. THE TEAM REFLECTS LEADING CARDIOLOGY, RA/OA, MAGNETICS, AND ROBOTICS EXPERTS. THE COMPANY MAINTAINS PARTNERSHIPS WITH LEADING NATIONAL LABORATORIES AND RECENTLY COMPLETED AN FDA PRESUBMISSION MEETING AND I-CORPS PARTICIPATION. THE PROPOSAL'S AIMS INCLUDE BUILDING A PROTOTYPE MAGNET SYSTEM, BUILDING MAGNETIC GUIDEWIRE AND ATHERECTOMY DEVICES, AND EVALUATING THE SYSTEM'S PERFORMANCE IN TORTUOUS CARDIAC PHANTOMS AND PUBLISHED LESION MODELS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 4/17/24 | ||
| Not listed | ($9k) | 8/5/22 | ||
| Not listed | ($9k) | 8/5/22 | ||
| Not listed | $8.7k | 6/3/22 | ||
| Not listed | $8.7k | 6/3/22 |